ETHYL 4-(4-(HYDROXYMETHYL)PIPERIDIN-1-YL)BENZOATE, 95.0%, 250mg

2-(3-Chlorothiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95+%, 100mg

(4-(Aminomethyl)-3-methylphenyl)(2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)methanone, 97%, 1g

4-(Piperidin-3-yl)morpholine dihydrochloride, 98%, 1g

1-Fluoro-3-(2-nitrovinyl)benzene, 95.0%, 1g

Dichlorobis(cyclopentadienyl)zirconium, 1g

n-(3-Aminopropyl)-N-methylacetamide, 98%, 1g

Methyl4-hydroxy-3,5-dimethyl-benzoate, 98+%, 1g

Joints, GL 45, 5 pièce(s)

2-(2-aminoethyl)-6-(2-furyl)pyridazin-3(2{H})-one, 95.0%, 500mg

1-((1-(Acryloyloxy)propan-2-yl)oxy)propan-2-yl acrylate, 80% (stabilized with 400ppm MEHQ), 5g

7-(tert-Butoxycarbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-3-carboxylic acid, 98%, 100mg

tert-Butyl(2-iodoethoxy)dimethylsilane, 95.0%, 1g